NEOG

Neogen Corporation (NEOG) and Where Food Comes From, Inc. (WFCF) are compared as investment opportunities in the food safety and agricultural verification sectors. NEOG demonstrates stronger growth momentum with 6.5% revenue growth, improving margins, and strategic initiatives like Petrifilm manufacturing transition and Genomics divestiture to reduce debt.

WFCF offers a more conservative balance sheet with improving profitability but faces challenges from slow revenue growth and heavy exposure to the struggling U.S. cattle industry. NEOG is positioned better for growth-focused investors despite higher debt, while WFCF appeals to conservative investors seeking stability.

The FDA issued a warning letter to Neogen Corporation on September 29, 2026, following an investigation linking its veterinary wound care product Neogen Vet HYCOAT to at least 20 horse deaths from serious infections. The contaminated sterile solution represents the largest number of horse deaths associated with a quality defect in an FDA-regulated veterinary product.

Neogen initiated a voluntary recall in January 2026. The announcement triggered a 7.22% stock price decline. Pomerantz LLP is investigating potential securities fraud claims on behalf of investors.

The Medical Products industry faces moderate growth prospects with resilient healthcare demand offset by tariff pressures and manufacturing costs. ICU Medical shows strong momentum in infusion systems with improving earnings, Neogen benefits from commercial execution improvements in food and animal safety, while Trulieve Cannabis expects growth acceleration from new markets like Georgia and Texas despite Florida seasonal softness.

Neogen reported Q1 2026 revenue of $222.8 million, up 6.5% year-over-year, beating the consensus estimate of $208.09 million by 7.07%. EPS came in at $0.08 versus the estimate of $0.05, representing a 60% surprise.

The company showed strong performance across most segments, with Food Safety revenue at $163.2 million and Animal Safety at $59.6 million, both exceeding analyst expectations. The stock has a Zacks Rank #2 (Buy) rating.

Neogen reported quarterly earnings of $0.08 per share, beating consensus estimates of $0.05 and marking a 60% earnings surprise. The company also exceeded revenue expectations with $222.8 million, up from $209.19 million year-over-year.

Despite strong performance, Neogen's Medical-Products industry ranks in the bottom 35% of Zacks industries. The stock has gained 86.1% year-to-date and holds a Zacks Rank #2 (Buy) rating.

Neogen (NEOG) shares have surged 83% year-to-date, outperforming the S&P 500, driven by strong Food Safety segment growth with core revenue increases of 5.8% in Q4 fiscal 2026. The company is expanding manufacturing capabilities following its 3M Food Safety acquisition, planning a 50% increase in R&D spending for fiscal 2027 focused on pathogen detection and sanitation platforms. However, fiscal 2027 EPS is projected to decline 3.1% before recovering with 17.2% growth in fiscal 2028.

A comparison of two Medical-Products stocks reveals that Prestige Consumer Healthcare (PBH) offers superior value compared to Neogen (NEOG). While both companies share a Zacks Rank #2 (Buy) rating with improving earnings outlooks, PBH demonstrates significantly better valuation metrics with a forward P/E of 10.26 versus NEOG's 41.51, a PEG ratio of 1.47 versus 4.15, and a Value grade of A versus D.

The global veterinary diagnostics market is projected to grow from USD 11.76 billion in 2025 to USD 30.78 billion by 2035, driven by increasing pet ownership, zoonotic disease surveillance, and advancements in point-of-care testing and molecular diagnostics. North America leads with 39% market share, while Asia-Pacific shows the fastest growth. Reagents & kits dominate products, while companion animals represent 61% of the market.